Previous Close | 18.53 |
Open | 18.81 |
Bid | 18.52 x 2200 |
Ask | 18.58 x 900 |
Day's Range | 18.51 - 19.08 |
52 Week Range | 18.47 - 34.73 |
Volume | |
Avg. Volume | 5,603,649 |
Market Cap | 3.066B |
Beta (5Y Monthly) | 1.10 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -24.33 |
Earnings Date | Oct 24, 2023 - Oct 30, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 29.39 |
Subscribe to Yahoo Finance Plus to view Fair Value for TDOC
The company's current lineup includes the t:slim X2 and the newly cleared Mobi Insulin Pump, which management calls "the world's smallest durable insulin delivery system." Despite this progress on the regulatory front, Tandem has been bruised and battered on the stock market over the past year, as its financial results haven't been as good. The company's sales of insulin pumps have declined amid the challenging economy, leading to lower year-over-year revenue growth.
Teladoc's (TDOC) BetterHelp business is expected to gain from new member growth and stable customer acquisition costs.
These companies haven't performed at pandemic levels, but investors may be overlooking some key green flags.